A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache

PHASE2CompletedINTERVENTIONAL
Enrollment

414

Participants

Timeline

Start Date

July 7, 2014

Primary Completion Date

August 19, 2015

Study Completion Date

February 12, 2018

Conditions
Migraine Headache
Interventions
DRUG

Galcanezumab

Administered SQ

DRUG

Placebo

Administered SQ

Trial Locations (40)

11803

Island Neuro Associates,PC, Plainview

14609

Rochester Clinical Research, Inc., Rochester

19107

Thomas Jefferson University, Philadelphia

21208

PharmaSite Research Inc, Baltimore

27103

PMG Research of Winston-Salem, LLC, Winston-Salem

27408

PharmQuest, Greensboro

29464

Coastal Carolina Research Center, Inc., Mt. Pleasant

32720

Avail Clinical Research LLC, DeLand

32751

Florida Clinical Research Center LLC, Maitland

32801

Psychiatric Inst of Florida-Clinical Neuroscience Solutions, Orlando

33407

Premiere Research Institute at Palm Beach Neurology, West Palm Beach

34471

Renstar Medical Research, Ocala

38119

CNS Health Care, Memphis

41017

Otri-Med Corporation, Edgewood

48104

Michigan Head, Pain and Neurological Institute, Ann Arbor

49009

Westside Family Medical Center, Kalamazoo

53562

Dean Foundation for Health Research and Education, Middleton

63141

Mercy Health Research, St Louis

68507

ClinVest, Springfield

78731

FutureSearch Trials, Austin

78759

DermResearch, Austin

80304

Alpine Clinical Research Center, Boulder

85004

21st Century Neurology, Phoenix

85023

Arizona Research Center, Phoenix

85234

Clinical Research Advantage, Gilbert

87102

Albuquerque Clinical Trials, Albuquerque

90404

California Medical Clinic for Headache, Santa Monica

90720

Pharmacology Research Institute, Long Beach, Los Alamitos

90806

Collaborative Neuroscience Network - CNS, Long Beach

91316

Pharmacology Research Institute, Long Beach, Encino

92013

Artemis Institute for Clinical Research, San Diego

92108

Medical Center for Clinical Research, San Diego

92270

Desert Valley Research, Rancho Mirage

92660

Pharmacology Research Institute, Long Beach, Newport Beach

94109

San Francisco Clinical Research Center, San Francisco

97210

Summit Research Network Inc, Portland

98007

Northwest Clinical Research Center, Bellevue

98105

North Seattle Womens Group, Seattle

06905

New England Institute for Clinical Research, Stamford

02131

Boston Clinical Trials Inc, Boston

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02163993 - A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache | Biotech Hunter | Biotech Hunter